目次

TABLE OF CONTENTS

1. EXECUTIVE SUMMARY

2. MARKET INTRODUCTION
2.1. Definition
2.2. Scope of the Study
2.2.1. Research Objective
2.2.2. Assumptions
2.2.3.Limitations

3. RESEARCH METHODOLOGY
3.1. Overview
3.2. Data Mining
3.3. Secondary Research
3.4. Primary Research
3.4.1. Primary Interviews and Information Gathering Process
3.4.2.Breakdown of Primary Respondents
3.5. Forecasting Model
3.6. Market Size Estimation
3.6.1. Bottom-Up Approach
3.6.2. Top-Down Approach
3.7. Data Triangulation
3.8. Validation

4. MARKET DYNAMICS
4.1. Overview
4.2. Drivers
4.3. Restraints
4.4. Opportunities

5. MARKET FACTOR ANALYSIS
5.1. Value Chain Analysis
5.2. Porter’s Five Forces Analysis
5.2.1. Bargaining Power of Suppliers
5.2.2. Bargaining Power of Buyers
5.2.3. Threat of New Entrants
5.2.4. Threat of Substitutes
5.2.5. Intensity of Rivalry
5.3. COVID-19 Impact Analysis
5.3.1. Market Impact Analysis
5.3.2. Regional Impact
5.3.3. Opportunity and Threat Analysis

6. GLOBAL INTERFERON BETA DRUGS MARKET, BY PRODUCT TYPE
6.1. Overview
6.2. Interferon Beta-1A
6.3. Interferon Beta-1B
6.4. Peginterferon Beta-1A

7. GLOBAL INTERFERON BETA DRUGS MARKET, BY ROUTE OF ADMINISTRATION
7.1. Overview
7.2. Intramuscular
7.3. Subcutaneous
7.4. Intravenous

8. GLOBAL INTERFERON BETA DRUGS MARKET, BY DISTRIBUTION CHANNEL
8.1. Overview
8.2. Hospitals Pharmacies
8.3. Retail Pharmacies
8.4. Online Pharmacies

9. GLOBAL INTERFERON BETA DRUGS MARKET, BY REGION
9.1. Overview
9.1. North America
9.1.1. US
9.1.2. Canada
9.2. Europe
9.2.1. Germany
9.2.2. France
9.2.3. UK
9.2.4. Italy
9.2.5. Spain
9.2.6. Rest of Europe
9.3. Asia-Pacific
9.3.1. China
9.3.2. India
9.3.3. Japan
9.3.4. South Korea
9.3.5. Australia
9.3.6. Rest of Asia-Pacific
9.4. Rest of the World
9.4.1. Middle East
9.4.2. Africa
9.4.3. Latin America

10. COMPETITIVE LANDSCAPE
10.1. Overview
10.2. Competitive Analysis
10.3. Market Share Analysis
10.4. Major Growth Strategy in the Global Interferon Beta Drugs Market,
10.5. Competitive Benchmarking
10.6. Leading Players in Terms of Number of Developments in the Global Interferon Beta Drugs Market,
10.7. Key Developments and Growth Strategies
10.7.1. New Product Launch/Service Deployment
10.7.2. Merger & Acquisitions
10.7.3. Joint Ventures
10.8. Major Players Financial Matrix
10.8.1. Sales & Operating Income, 2023
10.8.2. Major Players R&D Expenditure. 2023

11. COMPANY PROFILES
11.1. A S Biotech
11.1.1. Company Overview
11.1.2. Financial Overview
11.1.3. Products Offered
11.1.4. Key Developments
11.1.5. SWOT Analysis
11.1.6. Key Strategies
11.2. Novartis AG
11.2.1. Company Overview
11.2.2. Financial Overview
11.2.3. Products Offered
11.2.4. Key Developments
11.2.5. SWOT Analysis
11.2.6. Key Strategies
11.3. Apple Pharmaceuticals
11.3.1. Company Overview
11.3.2. Financial Overview
11.3.3. Products Offered
11.3.4. Key Developments
11.3.5. SWOT Analysis
11.3.6. Key Strategies
11.4. Hoffmann-La Roche Ltd
11.4.1. Company Overview
11.4.2. Financial Overview
11.4.3. Products Offered
11.4.4. Key Developments
11.4.5. SWOT Analysis
11.4.6. Key Strategies
11.5. Bayer
11.5.1. Company Overview
11.5.2. Financial Overview
11.5.3. Products Offered
11.5.4. Key Developments
11.5.5. SWOT Analysis
11.5.6. Key Strategies
11.6. Merck KGaA
11.6.1. Company Overview
11.6.2. Financial Overview
11.6.3. Products Offered
11.6.4. Key Developments
11.6.5. SWOT Analysis
11.6.6. Key Strategies
11.7. Mili Healthcare
11.7.1. Company Overview
11.7.2. Financial Overview
11.7.3. Products Offered
11.7.4. Key Developments
11.7.5. SWOT Analysis
11.7.6. Key Strategies
11.8. Biogen Idec
11.8.1. Company Overview
11.8.2. Financial Overview
11.8.3. Products Offered
11.8.4. Key Developments
11.8.5. SWOT Analysis
11.8.6. Key Strategies
11.9. Pfizer Inc
11.9.1. Company Overview
11.9.2. Financial Overview
11.9.3. Products Offered
11.9.4. Key Developments
11.9.5. SWOT Analysis
11.9.6. Key Strategies
11.10. Rewine Pharmaceutical
11.10.1. Company Overview
11.10.2. Financial Overview
11.10.3. Products Offered
11.10.4. Key Developments
11.10.5. SWOT Analysis
11.10.6. Key Strategies

12. APPENDIX
12.1. References
12.2. Related Reports

LIST OF TABLES
TABLE 1 GLOBAL INTERFERON BETA DRUGS MARKET, SYNOPSIS, 2019-2032
TABLE 2 GLOBAL INTERFERON BETA DRUGS MARKET, ESTIMATES & FORECAST, 2019-2032 (USD BILLION)
TABLE 3 GLOBAL INTERFERON BETA DRUGS MARKET, BY PRODUCT TYPE, 2019-2032 (USD BILLION)
TABLE 4 GLOBAL INTERFERON BETA DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2032 (USD BILLION)
TABLE 5 GLOBAL INTERFERON BETA DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019-2032 (USD BILLION)
TABLE 6 NORTH AMERICA: INTERFERON BETA DRUGS MARKET, BY PRODUCT TYPE, 2019-2032 (USD BILLION)
TABLE 7 NORTH AMERICA: INTERFERON BETA DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2032 (USD BILLION)
TABLE 8 NORTH AMERICA: INTERFERON BETA DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019-2032 (USD BILLION)
TABLE 9 US: INTERFERON BETA DRUGS MARKET, BY PRODUCT TYPE, 2019-2032 (USD BILLION)
TABLE 10 US: INTERFERON BETA DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2032 (USD BILLION)
TABLE 11 US: INTERFERON BETA DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019-2032 (USD BILLION)
TABLE 12 CANADA: INTERFERON BETA DRUGS MARKET, BY PRODUCT TYPE, 2019-2032 (USD BILLION)
TABLE 13 CANADA: INTERFERON BETA DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2032 (USD BILLION)
TABLE 14 CANADA: INTERFERON BETA DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019-2032 (USD BILLION)
TABLE 1 EUROPE: INTERFERON BETA DRUGS MARKET, BY PRODUCT TYPE, 2019-2032 (USD BILLION)
TABLE 2 EUROPE: INTERFERON BETA DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2032 (USD BILLION)
TABLE 3 EUROPE: INTERFERON BETA DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019-2032 (USD BILLION)
TABLE 4 GERMANY: INTERFERON BETA DRUGS MARKET, BY PRODUCT TYPE, 2019-2032 (USD BILLION)
TABLE 5 GERMANY: INTERFERON BETA DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2032 (USD BILLION)
TABLE 6 GERMANY: INTERFERON BETA DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019-2032 (USD BILLION)
TABLE 7 FRANCE: INTERFERON BETA DRUGS MARKET, BY PRODUCT TYPE, 2019-2032 (USD BILLION)
TABLE 8 FRANCE: INTERFERON BETA DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2032 (USD BILLION)
TABLE 9 FRANCE: INTERFERON BETA DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019-2032 (USD BILLION)
TABLE 10 ITALY: INTERFERON BETA DRUGS MARKET, BY PRODUCT TYPE, 2019-2032 (USD BILLION)
TABLE 11 ITALY: INTERFERON BETA DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2032 (USD BILLION)
TABLE 12 ITALY: INTERFERON BETA DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019-2032 (USD BILLION)
TABLE 13 SPAIN: INTERFERON BETA DRUGS MARKET, BY PRODUCT TYPE, 2019-2032 (USD BILLION)
TABLE 14 SPAIN: INTERFERON BETA DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2032 (USD BILLION)
TABLE 15 SPAIN: INTERFERON BETA DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019-2032 (USD BILLION)
TABLE 16 UK: INTERFERON BETA DRUGS MARKET, BY PRODUCT TYPE, 2019-2032 (USD BILLION)
TABLE 17 UK: INTERFERON BETA DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2032 (USD BILLION)
TABLE 18 UK: INTERFERON BETA DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019-2032 (USD BILLION)
TABLE 19 REST OF EUROPE: INTERFERON BETA DRUGS MARKET, BY PRODUCT TYPE, 2019-2032 (USD BILLION)
TABLE 20 REST OF EUROPE: INTERFERON BETA DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2032 (USD BILLION)
TABLE 21 REST OF EUROPE: INTERFERON BETA DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019-2032 (USD BILLION)
TABLE 22 ASIA-PACIFIC: INTERFERON BETA DRUGS MARKET, BY PRODUCT TYPE, 2019-2032 (USD BILLION)
TABLE 23 ASIA-PACIFIC: INTERFERON BETA DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2032 (USD BILLION)
TABLE 24 ASIA-PACIFIC: INTERFERON BETA DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019-2032 (USD BILLION)
TABLE 25 JAPAN: INTERFERON BETA DRUGS MARKET, BY PRODUCT TYPE, 2019-2032 (USD BILLION)
TABLE 26 JAPAN: INTERFERON BETA DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2032 (USD BILLION)
TABLE 27 JAPAN: INTERFERON BETA DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019-2032 (USD BILLION)
TABLE 28 CHINA: INTERFERON BETA DRUGS MARKET, BY PRODUCT TYPE, 2019-2032 (USD BILLION)
TABLE 29 CHINA: INTERFERON BETA DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2032 (USD BILLION)
TABLE 30 CHINA: INTERFERON BETA DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019-2032 (USD BILLION)
TABLE 31 INDIA: INTERFERON BETA DRUGS MARKET, BY PRODUCT TYPE, 2019-2032 (USD BILLION)
TABLE 32 INDIA: INTERFERON BETA DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2032 (USD BILLION)
TABLE 33 INDIA: INTERFERON BETA DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019-2032 (USD BILLION)
TABLE 34 AUSTRALIA: INTERFERON BETA DRUGS MARKET, BY PRODUCT TYPE, 2019-2032 (USD BILLION)
TABLE 35 AUSTRALIA: INTERFERON BETA DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2032 (USD BILLION)
TABLE 36 AUSTRALIA: INTERFERON BETA DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019-2032 (USD BILLION)
TABLE 37 SOUTH KOREA: INTERFERON BETA DRUGS MARKET, BY PRODUCT TYPE, 2019-2032 (USD BILLION)
TABLE 38 SOUTH KOREA: INTERFERON BETA DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2032 (USD BILLION)
TABLE 39 SOUTH KOREA: INTERFERON BETA DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019-2032 (USD BILLION)
TABLE 40 REST OF ASIA-PACIFIC: INTERFERON BETA DRUGS MARKET, BY PRODUCT TYPE, 2019-2032 (USD BILLION)
TABLE 41 REST OF ASIA-PACIFIC: INTERFERON BETA DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2032 (USD BILLION)
TABLE 42 REST OF ASIA-PACIFIC: INTERFERON BETA DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019-2032 (USD BILLION)
TABLE 43 REST OF THE WORLD: INTERFERON BETA DRUGS MARKET, BY PRODUCT TYPE, 2019-2032 (USD BILLION)
TABLE 44 REST OF THE WORLD: INTERFERON BETA DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2032 (USD BILLION)
TABLE 45 REST OF THE WORLD: INTERFERON BETA DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019-2032 (USD BILLION)
TABLE 46 MIDDLE EAST: INTERFERON BETA DRUGS MARKET, BY PRODUCT TYPE, 2019-2032 (USD BILLION)
TABLE 47 MIDDLE EAST: INTERFERON BETA DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2032 (USD BILLION)
TABLE 48 MIDDLE EAST: INTERFERON BETA DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019-2032 (USD BILLION)
TABLE 49 AFRICA: INTERFERON BETA DRUGS MARKET, BY PRODUCT TYPE, 2019-2032 (USD BILLION)
TABLE 50 AFRICA: INTERFERON BETA DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2032 (USD BILLION)
TABLE 51 AFRICA: INTERFERON BETA DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019-2032 (USD BILLION)
TABLE 52 LATIN AMERICA: INTERFERON BETA DRUGS MARKET, BY PRODUCT TYPE, 2019-2032 (USD BILLION)
TABLE 53 LATIN AMERICA: INTERFERON BETA DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2032 (USD BILLION)
TABLE 54 LATIN AMERICA: INTERFERON BETA DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019-2032 (USD BILLION)

LIST OF FIGURES
FIGURE 1 RESEARCH PROCESS
FIGURE 2 MARKET STRUCTURE FOR THE GLOBAL INTERFERON BETA DRUGS MARKET
FIGURE 3 MARKET DYNAMICS FOR THE GLOBAL INTERFERON BETA DRUGS MARKET
FIGURE 4 GLOBAL INTERFERON BETA DRUGS MARKET, SHARE (%), BY PRODUCT TYPE, 2023
FIGURE 5 GLOBAL INTERFERON BETA DRUGS MARKET, SHARE (%), BY ROUTE OF ADMINISTRATION, 2023
FIGURE 6 GLOBAL INTERFERON BETA DRUGS MARKET, SHARE (%), BY DISTRIBUTION CHANNEL, 2023
FIGURE 7 GLOBAL INTERFERON BETA DRUGS MARKET, SHARE (%), BY REGION, 2023
FIGURE 8 NORTH AMERICA: INTERFERON BETA DRUGS MARKET, SHARE (%), BY REGION, 2023
FIGURE 9 EUROPE: INTERFERON BETA DRUGS MARKET, SHARE (%), BY REGION, 2023
FIGURE 10 ASIA-PACIFIC: INTERFERON BETA DRUGS MARKET, SHARE (%), BY REGION, 2023
FIGURE 11 REST OF THE WORLD: INTERFERON BETA DRUGS MARKET, SHARE (%), BY REGION, 2023
FIGURE 12 GLOBAL INTERFERON BETA DRUGS MARKET: COMPANY SHARE ANALYSIS, 2023 (%)
FIGURE 13 A S BIOTECH: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 14 A S BIOTECH: SWOT ANALYSIS
FIGURE 15 NOVARTIS AG: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 16 NOVARTIS AG: SWOT ANALYSIS
FIGURE 17 APPLE PHARMACEUTICALS: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 18 APPLE PHARMACEUTICALS: SWOT ANALYSIS
FIGURE 19 HOFFMANN-LA ROCHE LTD: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 20 HOFFMANN-LA ROCHE LTD: SWOT ANALYSIS
FIGURE 21 BAYER: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 22 BAYER: SWOT ANALYSIS
FIGURE 23 MERCK KGAA: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 24 MERCK KGAA: SWOT ANALYSIS
FIGURE 25 MILI HEALTHCARE: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 26 MILI HEALTHCARE: SWOT ANALYSIS
FIGURE 27 BIOGEN IDEC: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 28 BIOGEN IDEC: SWOT ANALYSIS
FIGURE 29 PFIZER INC: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 30 PFIZER INC: SWOT ANALYSIS
FIGURE 31 REWINE PHARMACEUTICAL: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 32 REWINE PHARMACEUTICAL: SWOT ANALYSIS